Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04633187 · ClinicalTrials.gov registry record · Phase 2
Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract
A Phase 2 study, sponsored by Enanta Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT04633187 is a Phase 2 study that was terminated before completion, run by Enanta Pharmaceuticals. The registered enrollment target is 9 participants.
The verdict
NCT04633187, a Phase 2 study, was terminated before completion, sponsored by Enanta Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This was a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of EDP-938 in HCT recipients with acute RSV infection and symptoms of URTI.
Interventions
- DRUG Placebo
- DRUG EDP-938
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-07-07 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04633187
The ClinicalTrials.gov registry entry for NCT04633187 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04633187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04633187 about?
NCT04633187 is a clinical study titled "Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract". This was a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of EDP-938 in HCT recipients with acute RSV infection and symptoms of URTI.
What is the current status of trial NCT04633187?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2021-07-07. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT04633187?
The interventions under investigation include: Placebo (DRUG), EDP-938 (DRUG).
Who is sponsoring clinical trial NCT04633187?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.